These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9491285)

  • 1. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S; Plavljanić E; Trkulja V
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.
    Granolleras C; Leskopf W; Shaldon S; Fourcade J
    Clin Nephrol; 1991 Dec; 36(6):294-8. PubMed ID: 1769141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
    Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
    Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M; Premru V
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients.
    Schmitt CP; Nau B; Brummer C; Rosenkranz J; Schaefer F
    Nephrol Dial Transplant; 2006 Dec; 21(12):3520-4. PubMed ID: 16935904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A; Malagoli A; Komninos G; Pastori G
    J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help?
    Morris KP; Hughes C; Hardy SP; Matthews JN; Coulthard MG
    Nephrol Dial Transplant; 1994; 9(9):1299-301. PubMed ID: 7816294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha.
    Yu AW; Leung CB; Li PK; Lui SF; Lai KN
    Int J Artif Organs; 1998 Jun; 21(6):341-3. PubMed ID: 9714028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
    Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.